Direkt zum Inhalt
Merck
  • Evaluation of the matrix effect of different sample matrices for 33 pharmaceuticals by post-column infusion.

Evaluation of the matrix effect of different sample matrices for 33 pharmaceuticals by post-column infusion.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2015-07-27)
Julia Rossmann, Robert Gurke, Lars David Renner, Reinhard Oertel, Wilhelm Kirch
ZUSAMMENFASSUNG

Matrix effects that occur during quantitative measurement by liquid chromatography mass spectrometry specifically when using electrospray ionization are a widely recognized phenomenon. Sample matrix compounds affect the ionization process of the target analytes, lead to a low signal response, and flawed analytical results. How these matrix compounds directly influence the ionization process has not yet been completely understood. In the present study, we determined the matrix effect for 33 pharmaceutical substances in sample extracts of urine, plasma and wastewater. Most of the investigated substances were subject to a signal suppression effect. Only for a small subset of the compounds we detected a signal enhancement effect. We investigated the matrix effect profiles in detail to disentangle the influence of different matrices and to correlate the impact of specific components and groups of the analyzed extract in suppressing or enhancing effects in the profile. Most signal suppression effects were detected in the first half of the chromatographic run-time for the matrix extracts of urine and wastewater. The observed effects are caused by high mass flow of salts and other diverse matrix components that were contained in high concentrations in those biological matrices. We also found signal suppression in the matrix effect profile of plasma samples over a wide time range during the chromatographic separation that were associated with a high content of triglycerides of diverse carbohydrate chain lengths. Here, we provide a broader picture of how 33 substances were influenced during analysis. Our results imply that a high number of the investigated substances had comparable effects of matrix compounds, despite differences in their chemical structure.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Fluconazol, ≥98% (HPLC), powder
Sigma-Aldrich
Carbamazepin, powder
Sigma-Aldrich
Ameisensäure, ≥95%, FCC, FG
Supelco
Pregabalin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Clozapin
Sigma-Aldrich
Haloperidol, powder
Sigma-Aldrich
Lamotrigin, ≥98%, powder
Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Supelco
Gabapentin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Gabapentin, solid
Supelco
Clozapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Olanzapin, ≥98% (HPLC)
Supelco
Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Risperidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Mirtazapin, ≥98% (HPLC)
Supelco
Levetiracetam -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Mirtazapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Oxcarbazepin, ≥98% (HPLC), solid
Supelco
Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®